A5046019609- Traditional Chinese Medicine Studies
- Parkinson's Disease Mechanisms and Treatments
- Cardiac Ischemia and Reperfusion
- Traditional Chinese Medicine Analysis
- Alzheimer's disease research and treatments
- Lung Cancer Treatments and Mutations
- Adipose Tissue and Metabolism
- Inflammatory mediators and NSAID effects
- Colorectal Cancer Treatments and Studies
- Cellular transport and secretion
- Pharmacological Effects of Natural Compounds
- Mitochondrial Function and Pathology
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- RNA Interference and Gene Delivery
- Eosinophilic Disorders and Syndromes
- Neuroinflammation and Neurodegeneration Mechanisms
- Virus-based gene therapy research
- Lipid metabolism and disorders
- Advanced Glycation End Products research
- Atherosclerosis and Cardiovascular Diseases
- Bone Metabolism and Diseases
- Cancer Treatment and Pharmacology
- Sepsis Diagnosis and Treatment
- Neuroscience and Neuropharmacology Research
Hong Kong Polytechnic University
2022-2025
Liaoning University of Traditional Chinese Medicine
2007-2025
Chinese University of Hong Kong
2016-2025
Shanghai Sixth People's Hospital
2021-2024
Shanghai Jiao Tong University
2012-2024
AstraZeneca (United Kingdom)
2023-2024
Harbin Medical University
2010-2024
Second Affiliated Hospital of Harbin Medical University
2006-2024
First Affiliated Hospital of Heilongjiang University of Chinese Medicine
2024
AstraZeneca (United States)
2023-2024
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA.MethodsWe conducted multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate efficacy and safety of benralizumab as compared mepolizumab. Adults relapsing or refractory EGPA who were receiving...
Myoblast transplantation has been proposed as a potential therapy for Duchenne muscular dystrophy (DMD). A Y-chromosome-specific probe was used to track the fate of donor male myoblasts injected into dystrophic muscles female mdx mice (which are an animal model DMD). In situ analysis with Y-probe showed extremely poor survival isolated normal (C57B1/10Sn) after injection injured or uninjured (mdx) and host mice. decrease in numbers (male) seen from 2 days marked by 7 injection: few no were...
There is compelling evidence for the role of leucine-rich repeat kinase 2 (LRRK2) and in particular its function Parkinson's disease. Orally bioavailable, brain penetrant potent LRRK2 inhibitors are later stages clinical development. Here, we describe a facile robust assay to quantify pathway activity by measuring LRRK2-mediated phosphorylation Rab10 human peripheral blood neutrophils. We use selective MJFF-pRab10 monoclonal antibody recognising Thr73 phospho-epitope that phosphorylated...
Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein with both Ras of complex (ROC) domain and (KD) and, therefore, exhibits GTPase activities. Human genetics studies have linked LRRK2 as major genetic contributor to familial sporadic Parkinson’s disease (PD), neurodegenerative movement disorder that inflicts millions worldwide. The C-terminal region Trp-Asp-40 (WD40) poorly defined biological functions but has been implicated in microtubule interaction. Here, we present the...
Abstract Forkhead box protein O1 (FOXO1), a nuclear transcription factor, is preferably activated in the myocardium of diabetic mice. However, its role and mechanism development cardiomyopathy non‐obese insulin‐deficient diabetes are unclear. We hypothesized that cardiac FOXO1 over‐activation was attributable to imbalanced myocardial oxidative metabolism mitochondrial dysfunction type 1 diabetes. FOXO1‐selective inhibitor AS1842856 administered streptozotocin‐induced (D) rats, functions,...
Abstract Heterozygous gain-of-kinase function variants in LRRK2 (leucine-rich repeat kinase 2) cause 1–2% of all cases Parkinson’s disease (PD) albeit with incomplete and age-dependent penetrance. All pathogenic mutations reside within the two catalytic domains LRRK2—either its domain (e.g. G2019S) modest effect or ROC-COR GTPase R1441G/H) large on activity. We have previously reported assays to interrogate pathway activity human bio-samples measuring phosphorylation endogenous substrate...
Atherosclerosis is a chronic inflammatory arterial disease characterized by build-up of atheromatous plaque, which narrows the lumen arteries. Hypercholesterolemia and excessive oxidative stress in walls are among main causative factors atherosclerosis. Transient receptor potential channel M2 (TRPM2) Ca2+-permeable cation activated stress. However, role TRPM2 atherosclerosis animal models not well studied. In present study, with use adeno-associated virus (AAV)-PCSK9 knockout (TRPM2−/−)...
Background . Activation of cell apoptosis is a major form death during myocardial ischemia/reperfusion injury (I/RI). Therefore, examining ways to control has important clinical significance for improving postischemic recovery. Clinical evidence demonstrated that miR-181c-5p was significantly upregulated in the early phase infarction. However, whether or not mediates cardiac I/RI through pathway unknown. Thus, present study aimed at investigating role and possible mechanism I/R by using H9C2...
Significance We used an unbiased screening strategy to capture deubiquitylases that participate in T cell receptor signaling primary cells under physiological settings. identified ubiquitin-specific peptidase (Usp) 12 as a crucial component of TCR expression at the surface, and found supporting evidence for its function by creating inducible genetic knockout Jurkat cells. Using proximity-based labeling, we LAT Trat1 substrates Usp12. In Usp12-deficient cells, both are ubiquitin-modified...
Highlights•Decreased Akk level is crucial for the development of MAFLD-induced HCC•Akk complements therapeutic efficacy PD1 therapy in induces T cell infiltration via suppression m-MDSCs and M2 macrophages•Akk as a potential biomarker predicting response survivalSummaryImmune checkpoint inhibitors are not effective metabolic dysfunction-associated fatty liver disease (MAFLD)-hepatocellular carcinoma (HCC) patients, identifying key gut microbiota that contributes to immune resistance these...
Background/Objective: Atherosclerosis is one of the leading causes cardiovascular diseases and mortality around world. One exciting strategy for atherosclerosis treatment immunotherapy, especially active immunization. Active immunization relies on delivery antigens in a vaccine platform to introduce humoral cellular immunity, alleviating atherosclerotic progression. Transient receptor potential channel isoform M2 (TRPM2) an ROS-activated Ca2+-permeable ion that can promote via stimulating...
Yi Mai granule (YMG) is a traditional Chinese medicine (TCM) herbal decoction consisting of two TCM formulas: Gua-Lou-Ban-Xia and Si-Jun-Zi decoction. YMG has shown clinical benefit in the treatment nonalcoholic fatty liver disease (NAFLD), which may be due to its regulatory effects on lipid metabolism. Previous studies have highlighted importance gut microbiota metabolites use TCM. However, effect NAFLD remains unclear. In this study, we established an model ApoE-/- mice treated them with...
Picroside II exerts anti-inflammatory and antidiarrheal effects for treating the diseases associated with oxidative injury. However, its function on pancreatitis-induced intestinal barrier injury remains unclear. Hypothesis/Purpose. We hypothesized that picroside will have protective against by affecting inflammatory signaling (Toll-like receptor 4- (TLR4-) dependent phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), nuclear factor kappa (NF-κB)). Study Design Methods. A...